Loading
Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.
A returnee antibody scientist who founded Akeso in 2012 and built the Tetrabody platform behind cadonilimab (PD-1 x CTLA-4, approved 2022), ivonescimab (PD-1 x VEGF, approved 2024, HARMONi-2 win over pembrolizumab) and penpulimab (FDA approved 2025); licensed ivonescimab's Western rights to Summit Therapeutics for $500 million upfront.
| Title | Journal | Year |
|---|---|---|
| Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors | Journal for ImmunoTherapy of Cancer | 2024 |
| Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer | 2022 |
| CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors | Cancer Immunology, Immunotherapy | 2024 |
Shares HARMONi-2, Ivonescimab and the tag china.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares HARMONi-A, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/